Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.

Eric A. Pierce(Broad Institute), Lois E. H. Smith(Boston Children's Hospital), E D Foley(Massachusetts Eye Research and Surgery Institute), Robert L. Avery(California Retina Consultants), L P Aiello(Boston Children's Hospital)
Proceedings of the National Academy of Sciences
January 31, 1995
10.1073/pnas.92.3.905
Cited by 1,035

Related Papers

Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864
Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor
|Diabetes|1997|669